Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21396408 | 0.96 | TDP1 (0.38) | ADORA3ADORA1TDP1 | |
| SCHEMBL21396351 | 0.86 | TDP1 (0.39) | ADORA3ADORA1TDP1 | |
| SCHEMBL21396469 | 0.84 | TDP1 (0.38) | ADORA3ADORA1TDP1 | |
| SCHEMBL21396464 | 0.84 | TDP1 (0.39) | ADORA3ADORA1TDP1 | |
| SCHEMBL21396385 | 0.83 | ADORA3 (0.37) | ADORA3ADORA1TDP1 | |
| SCHEMBL21396413 | 0.76 | ADORA3 (0.40) | ADORA3ADORA1TDP1 | |
| SCHEMBL20016042 | 0.76 | TDP1 (0.47) | ADORA3ADORA1TDP1 | |
| SCHEMBL21396436 | 0.73 | ADORA3 (0.52) | ADORA3ADORA1TDP1BCL2MCL1 | |
| SCHEMBL21396345 | 0.73 | TDP1 (0.38) | TDP1 | |
| SCHEMBL21396405 | 0.73 | TDP1 (0.38) | ADORA3ADORA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PDE7A, PRKG1, PDE4C | ADORA3 322/4885ADORA1 578/4885TDP1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.